Replies to post #31 on Theseus Pharmaceuticals Inc (THRX)

[surf1944]

September 7, 2012
07:14 EDT THRX, GSK Theravance recent weakness a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the recent weakness in shares of Theravance (THRX) as a buying opportunity as it believes Phase III data for Breo/Relvar and LAMA/LABA support regulatory approval and an eventual takeout by partner GlaxoSmithKline (GSK). Piper reiterates an Overweight rating on Theravance with a $35 price target.